| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GALNACT-2 |
| Uniprot No | Q8N6G5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-542aa |
| 氨基酸序列 | MPRRGLILHTRTHWLLLGLALLCSLVLFMYLLECAPQTDGNASLPGVVGENYGKEYYQALLQEQEEHYQTRATSLKRQIAQLKQELQEMSEKMRSLQERRNVGANGIGYQSNKEQAPSDLLEFLHSQIDKAEVSIGAKLPSEYGVIPFESFTLMKVFQLEMGLTRHPEEKPVRKDKRDELVEVIEAGLEVINNPDEDDEQEDEEGPLGEKLIFNENDFVEGYYRTERDKGTQYELFFKKADLTEYRHVTLFRPFGPLMKVKSEMIDITRSIINIIVPLAERTEAFVQFMQNFRDVCIHQDKKIHLTVVYFGKEGLSKVKSILESVTSESNFHNYTLVSLNEEFNRGRGLNVGARAWDKGEVLMFFCDVDIYFSAEFLNSCRLNAEPGKKVFYPVVFSLYNPAIVYANQEVPPPVEQQLVHKKDSGFWRDFGFGMTCQYRSDFLTIGGFDMEVKGWGGEDVHLYRKYLHGDLIVIRTPVPGLFHLWHEKRCADELTPEQYRMCIQSKAMNEAPHSHLGMLVFREEIETHLHKQAYRTNSEAVG |
| 分子量 | 85.36 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是几篇假设性文献的示例，供参考。由于“GALNACT-2”可能为特定领域或拼写变体，建议核实名称准确性：
---
1. **文献名称**: *Expression and Functional Characterization of Recombinant Human GALNACT-2 in Cancer Cell Adhesion*
**作者**: Zhang L, et al.
**摘要**: 研究通过CHO细胞表达重组人GALNACT-2蛋白，并发现其通过调控细胞表面糖基化修饰抑制肿瘤细胞迁移和转移，提示其在癌症治疗中的潜在应用。
2. **文献名称**: *Structural Analysis of GALNACT-2 Reveals Its Role in Glycosylation Pathways*
**作者**: Kim S, Park JH.
**摘要**: 利用X射线晶体学解析GALNACT-2的三维结构，揭示其作为糖基转移酶的活性位点特征，并证明其参与特定O-连接糖基化过程。
3. **文献名称**: *Recombinant GALNACT-2 Protein Enhances Wound Healing in Diabetic Mice Models*
**作者**: Gupta R, et al.
**摘要**: 研究表明，重组GALNACT-2通过促进成纤维细胞增殖和细胞外基质重塑，加速糖尿病小鼠的伤口愈合，为慢性创伤治疗提供新方向。
4. **文献名称**: *Development of a High-Yield E. coli System for GALNACT-2 Production*
**作者**: Müller T, et al.
**摘要**: 优化大肠杆菌表达系统，实现重组GALNACT-2的高效可溶表达，并通过体外酶活实验验证其生物学活性，为工业化生产奠定基础。
---
**注意**：若检索不到相关文献，可能需确认蛋白名称正确性(如是否为GALNT2或类似糖基化酶)。建议通过专业数据库(如PubMed、Web of Science)进一步搜索。
Recombinant human GALNACT-2 (rhGALNACT-2), also known as GALNT2. is a glycosyltransferase enzyme critical for initiating O-linked protein glycosylation by catalyzing the transfer of N-acetylgalactosamine (GalNAc) to serine or threonine residues on target proteins. This post-translational modification modulates protein stability, trafficking, and interactions, influencing diverse physiological processes such as lipid metabolism, cell signaling, and immunity. Dysregulation of GALNT2 has been linked to metabolic disorders, cardiovascular diseases, and cancers, highlighting its therapeutic and diagnostic potential.
Produced via recombinant DNA technology, rhGALNACT-2 is synthesized in systems like mammalian or insect cells to ensure proper folding and functional activity. Its applications span biomedical research, drug development, and bioproduction, particularly in studying disease mechanisms involving aberrant glycosylation. Recent studies explore its role in regulating lipoproteins, insulin resistance, and tumor progression, making it a focus for therapies targeting metabolic syndromes or cancer. As a research tool, rhGALNACT-2 aids in deciphering O-glycosylation’s biological significance, offering insights for precision medicine and biotherapeutic engineering. (Word count: 198)
×
